Answers are grounded in this paper and cite their sources.
This work shows enhanced binding affinity in MEF2A via peptide, indicating potential use in therapeutics for neurodegenerative diseases.
Myocyte enhancer-factor 2 (MEF2) transcription factors regulate neural crest development and neural survival. Class IIa histone deacetylases (HDACs) directly interact with MEF2s to repress their gene expression activity, which has a pivotal role in neuronal apoptosis. In this work, we designed a peptide that binds to MEF2A and blocks interaction between HDAC7 (a member of class IIa HDACs) and MEF2A (a member of MEF2s family) and has potential to enhance the MEF2 transcription activity. We modeled the peptide, predicted peptide-MEF2A complex and performed molecular dynamics (MD) simulations to characterize the complex formation. Analysis of root mean square deviation (RMSD) and radius of gyration (R g ), indicate the formation of a stable complex during the simulation. We also quantified the peptide-MEF2A binding affinity via calculation of molecular mechanics/generalized born surface area (MM/GBSA) binding free energy and the results indicated a favorable binding between the peptide and MEF2A. We further analyzed simulation trajectories to explore different specific interactions. We then designed a synthetic peptide using the same sequence as we used in MD simulations and conducted surface plasmon resonance (SPR)-based experiments. SPR results show that the synthetic peptide binds to MEF2A with a K D value of 67.7 nM. SPR results further show that the synthetic peptide is capable of blocking the HDAC7-MEF2A direct binding, which helps develop new therapeutics to combat neurodegenerative diseases.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: